Life Science Services
The journey from molecule discovery to commercialization can be long, costly, and complex. For biotechnology companies, finding the right partner to embark on the journey — or drive it forward — is essential. We are that partner for many — collaborating with leading drug developers and innovative startups — to help bring therapies and drugs to patients. Whether clients need support across the many steps of the drug manufacturing process, or they exclusively need testing and analytics, we find the right way to build a strong partnership.
Our support extends through the molecule’s entire value chain — from pre-clinical to commercialization. We provide drug manufacturers with robust infrastructure, technologies, and various testing platforms. Our vast inventory of essential products complements our robust services.
Driving drug development forward, wherever you are
We provide end-to-end solutions and best-in-class services for our clients worldwide as a leader across a wide range of modalities, including monoclonal antibodies and recombinant proteins (mAb and r-proteins), antibody-drug conjugates (ADC), viral vectors (VV), messenger RNA (mRNA), small molecules, lipid nanoparticles (LNP) and high-potent active pharmaceutical ingredients (HPAPI). We partner with a wide range of clients, from small start-ups to multinational companies.
Our Millipore® Contract Testing, Development, and Manufacturing Organization (CTDMO) Services global infrastructure allows us to tackle a broad range of quantities and tailor formulas accordingly. We develop, manufacture and test traditional and novel modalities. And we think of patients every step of the way. It’s why we’re investing in infrastructure around promising novel modalities that look past treatments and toward cures.
Ensuring the safety of the world’s medicines
Our BioReliance® biosafety testing and analytical development services support our global clients with over 75 years of technical and regulatory expertise. Our experience is deep, including testing the first polio vaccines in the 1950s and developing the first testing protocols for the inaugural gene therapy products in human trials by the Food and Drug Administration. From there, we have continued to deliver the highest quality testing services and regulatory expertise to bring life-changing medicines to patients. We help ensure the safety of the world’s biologics, leading innovation today and shaping the services of tomorrow.
To continue reading please sign in or create an account.
Don't Have An Account?